Inspire Medical Systems (NYSE:INSP) Given New $195.00 Price Target at Wells Fargo & Company

Inspire Medical Systems (NYSE:INSP) had its price target cut by Wells Fargo & Company from $198.00 to $195.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other equities analysts also recently commented on INSP. Stifel Nicolaus lowered their price target on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a report on Tuesday, January 21st. Robert W. Baird lifted their target price on shares of Inspire Medical Systems from $240.00 to $252.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Bank of America raised shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $220.00 to $255.00 in a research report on Wednesday, November 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $260.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Finally, Piper Sandler decreased their target price on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research note on Monday. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $228.82.

Inspire Medical Systems Trading Up 1.2 %

INSP stock opened at $183.17 on Tuesday. The firm has a market cap of $5.49 billion, a PE ratio of 171.18 and a beta of 1.32. Inspire Medical Systems has a 1 year low of $123.00 and a 1 year high of $257.40. The company has a fifty day simple moving average of $189.57 and a 200 day simple moving average of $190.98.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. As a group, analysts forecast that Inspire Medical Systems will post 1.33 EPS for the current fiscal year.

Institutional Trading of Inspire Medical Systems

A number of institutional investors and hedge funds have recently modified their holdings of INSP. First Horizon Advisors Inc. lifted its position in Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 124 shares during the period. True Wealth Design LLC acquired a new position in shares of Inspire Medical Systems in the 3rd quarter valued at $30,000. Farther Finance Advisors LLC lifted its holdings in shares of Inspire Medical Systems by 1,158.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after acquiring an additional 139 shares during the period. GAMMA Investing LLC boosted its position in shares of Inspire Medical Systems by 559.3% during the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock valued at $38,000 after acquiring an additional 151 shares in the last quarter. Finally, Harbour Investments Inc. increased its stake in Inspire Medical Systems by 101.0% in the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock valued at $37,000 after acquiring an additional 99 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.